How can life be made easier for people with epilepsy?
That was the question posed by Christer Sjögren, one of SWIPP’s two founders. Our story begins before 2017. After a successful career in the pharmaceutical industry, holding senior positions in several different companies, Christer decides to look for a new challenge. This turns out to be creating the best possible product for treating convulsive epilepsy seizures. The idea of the buccal film with midazolam is born, and soon thereafter he submits a patent application.
Bengt Westrin, the co-founder of SWIPP, has successfully developed and patented a medical oral film for another company. Christer Sjögren and Bengt Westrin are former colleagues, and decide to collaborate and pool their expertise. Bengt has extensive experience of pharmaceutical development and understands the necessary stages and conditions of a project.
In October 2017, SWIPP is founded. The company’s focus is the buccal midazolam film project, but it won’t be long before new ideas take shape.
Current events
Our history
August 2022
SWIPP’s second patent application is filed as a PCT version.
April 2022
The results of market research conducted by Drive Research (US) are released. Forty epilepsy specialists in the USA, the UK, Germany and France were asked about SWIPP’s buccal film (Project 1).
The responses showed unequivocally that they appreciated the product and that they would prescribe it if it were available.
April 2022
January 2022
November 2021
An unusually eventful month. A share issue is made, with 15 of the company’s 17 co-owners participating. Intensive preparations continue for SWIPP-012, and of SWIPP-011 which will be the first study within Project 2. Clinical trial applications submitted to the State Institute for Drug Control (SUKL) in the Czech Republic are approved, import and export licences are granted for the trial product, and a new GMP batch is manufactured. All deadlines are met!
August 2021
May 2021
March 2021
January 2021
Eight new co-owners are welcomed on board, including a number of successful entrepreneurs from the health care and biotech industries.
December 2020
April 2020
Mastan AB, AB Seglarevägen and Margaretha Cronvall are welcomed as new shareholders.
August 2019
May 2019
Advisory meeting with the Swedish Dental and Pharmaceutical Benefits Agency (TLV) regarding future pricing for SWIPP’s product.
February 2019
Scientific Advice Meeting with the Swedish MPA.
October 2018
Cooperation begins with the GMP manufacturer AdhexPharma in France. AdhexPharma also decides to invest in SWIPP.
September 2018
Cooperation begins with Quinta-Analytica in Prague, a one-stop-shop CRO specialized on Phase I studies and bioequivalence studies.
June 2018
Conducting 20 in-depth interviews with neurologists, parents and other caretakers in the epilepsy field. The product concept is well received. The pace picks up.
April 2018
Regulatory advice received from the Swedish Medical Products Agency (MPA/Läkemedelsverket) and from the MHRA in the UK.
February 2018
Cooperation begins with the regulatory advisor SOFUS in Stockholm (now ProPharma Group).
December 2017
Three seed investors who share SWIPP’s vision get on board: Lars Hedbys, Lars Persson, and Johan & Annette Säfholm.